Eden Hands Keys To CDMO Unit Over To Bora Pharmaceuticals
Taiwanese Biologics Developer Will Maintain Relationship With Spun-Out Unit
Eden Biologics has sold its CDMO business to Bora Pharmaceuticals’ recently-established biologics CDMO platform Bora Biologics. The firm appears keen to maintain a working relationship with its former unit following the sale.
You may also be interested in...
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Two former JHL Biotech executives have been handed prison sentences after pleading guilty to a charge of conspiracy to commit theft of trade secrets and wire fraud, in relation to the Taiwanese firm’s development of multiple biosimilars.
Two former JHL Biotech executives, Racho Jordanov and Rose Lin, have been convicted in the US of conspiracy to commit trade secret theft and wire fraud after submitting plea agreements. Meanwhile, the company – now named Eden Biologics – has just announced a change of CEO.